Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc is demonstrating a robust outlook due to the encouraging results of its Phase 2 trials for its lead product, vidofludimus calcium, which has shown significant effectiveness in treating relapsing multiple sclerosis, evidenced by improvements in lesion control and relapse prevention. The company has recently bolstered its financial position through a nearly $200 million financing, which will support further advancements in its clinical programs, including the pivotal Phase 3 ENSURE trials anticipated for completion by 2026. Furthermore, the positive momentum in clinical data and the clear path towards a potential New Drug Application (NDA) filing in 2027 reinforce the company's strategy and growth potential within the biopharmaceutical sector.

Bears say

Immunic Inc's negative outlook is influenced by several key factors, including the impending reverse stock split, which suggests underlying weakness in investor demand and introduces technical and dilution risks. This structural adjustment is perceived as detrimental to shareholder value, particularly as it could lead to reduced liquidity and lower retail participation, exacerbating volatility. Moreover, the company's reliance on the successful commercialization of its developmental candidates is fraught with risks, including potential failure to meet revenue expectations and challenges in securing necessary capital for continued operations.

Immunic Inc (IMUX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.